Navigation Links
OphthaliX Inc. Announces the Completion of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study
Date:3/15/2013

SOUTH JORDAN, Utah and PETACH TIKVAH, Israel, March 15, 2013 /PRNewswire/ -- OphthaliX Inc. (OTCBB: OPLI) announced today that it has completed patient enrollment for a Phase 3 clinical study of CF101 for the treatment of Dry Eye Syndrome (DES). The randomized, double-masked study is conducted in the United States, Europe and Israel. The study includes 236 patients with moderate-to-severe DES who are randomized to receive two oral doses of CF101 and a placebo for a period of 24 weeks. The results of this study are expected to be announced in the fourth quarter of 2013.

"We are very pleased to have completed the patient enrollment for our Dry Eye Syndrome study," commented Barak Singer , the CEO of OphthaliX. "Receiving additional clinical data is an important step for OphthaliX as we further develop CF101. We are looking forward to the results of this study which will be released during the fourth quarter this year."  

About OphthaliX Inc.
OphthaliX Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic products for the treatment of ophthalmic disorders. OphthaliX's product candidate, CF101, is being developed to treat three ophthalmic indications: dry eye syndrome; glaucoma and uveitis.

About CF101
CF101, an A3 adenosine receptor agonist, is a novel, first in class, small molecule, orally bioavailable drug which demonstrated efficacy and an excellent safety profile in Phase 2 clinical studies. CF101 is currently developed for ophthalmic indications, including dry eye syndrome (Phase 3), glaucoma (Phase 2) and Uveitis. CF101 is also developed for the treatment of autoimmune inflammatory diseases including rheumatoid arthritis (Phase 2b) and psoriasis (Phase 2/3).

Contact:
KCSA Strategic Communications
'/>"/>

SOURCE OphthaliX Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. OphthaliX Reports First Quarter 2012 Financial Results
2. Telik Announces Fourth Quarter And 2012 Year End Financial Results And 2013 Financial Guidance
3. ULURU Inc. Announces Closing Of $440,000 Private Placement
4. Cardica Announces Proposed Public Offering of Common Stock
5. PAREXEL International Provides Update On Share Repurchase Program, Announces A New $50 Million Accelerated Share Repurchase Agreement And A New $50 Million 10b5-1 Trading Plan
6. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
7. Simbionix Announces License Agreement for Surgical Videos
8. BioTrends Announces the Continuation of a Syndicated Report Series: TreatmentTrends: CKD Stages 1-5ND
9. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
10. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
11. PDI, Inc. Announces $17 Million Multi-Year Sales Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... HILL, Conn. , July 2, 2015 ... Chief Executive Officer announced that Tamas Feitel ... Feitel joins Numotion after a highly successful 18 ... finance leadership roles driving strategy, profitability, and productivity to ... His most recent position was Chief Financial Officer for ...
(Date:7/2/2015)... DURHAM, N.C. , July 2, 2015 ... of assets related to the ion channel biology platform ... previously been obtained as part of Pfizer,s 2011 acquisition ... Pfizer,s rights to the "Icagen" name and trademark.  XRPro ... comprehensive services for ion channel and transporter drug discovery, ...
(Date:7/2/2015)... TOKYO , July 2, 2015  Konica Minolta, ... today announced that it has acquired Sawae Technologica Ltda., ... Brazil , through its Brazilian healthcare ... . Local Brazil ... increasing population exceeding 200 million, significant healthcare ...
Breaking Medicine Technology:Numotion Names Tamas Feitel Chief Financial Officer 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 2Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 3
... Making uninformed decisions in today,s new and ... kind of small missteps that briefly disrupt productivity ... negative media attention. Savvy pharmaceutical executives base direction-changing ... To support pharmaceutical vice presidents, directors, and ...
... UCB, a leading biopharmaceutical company at the forefront of ... Cimzia® (certolizumab pegol) at the American College of Gastroenterology ... from October 28 to November 2.   ... the role that inflammatory biomarkers may play in increasing ...
Cached Medicine Technology:Pharmaceutical Executives Use New Search Function for Data-Informed Decision-Making 2New Data on Cimzia® (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease 2New Data on Cimzia® (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease 3New Data on Cimzia® (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease 4New Data on Cimzia® (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease 5New Data on Cimzia® (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease 6New Data on Cimzia® (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease 7New Data on Cimzia® (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease 8New Data on Cimzia® (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease 9New Data on Cimzia® (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease 10New Data on Cimzia® (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease 11
(Date:7/2/2015)... ... July 02, 2015 , ... AvePoint Public Sector, Inc., a wholly ... and devices, today announced it was named the recipient of the 2015 GTRA ConVurge ... given out by the Government Technology Research Alliance (GTRA), was presented June 29 during ...
(Date:7/2/2015)... ... ... arrests and fatalities spike on the 4th of July. In fact, because of drunk drivers, ... to being on the road. According to attorney David J. Maloney , the statistics ... deaths between 2007 and 2011 were caused by drunk driving over the 4th of July ...
(Date:7/2/2015)... Yorba Lind, CA (PRWEB) , ... July 02, 2015 , ... ... Dunne, PhD, QC manager, have adopted Lean methodology in their QC laboratory for enhanced ... Certified Lean Six Sigma Laboratory within the GE Healthcare Diagnostic Imaging network. ...
(Date:7/2/2015)... ... 2015 , ... As part of the celebration of its 70th anniversary, the ... its patients from all around the world for their continuous patronage of the world-class ... a dental tour (indeed, Thantakit is one of the foremost places for dental tourism ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... with nutritionally based weight-loss programs , was named No. 14 on ColoradoBiz ... this is the third year SlimGenics has been recognized. The award identifies outstanding ...
Breaking Medicine News(10 mins):Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 2Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 4Health News:Attorney David Maloney Stresses Safety through Sobriety 2Health News:GE Healthcare Webinar Spotlights GE’s Own, Internal QC Lab Enhancements with Six Sigma 2Health News:GE Healthcare Webinar Spotlights GE’s Own, Internal QC Lab Enhancements with Six Sigma 3Health News:Thailand's Longest Established International Dental Center Celebrates Its 70th Anniversary with Promos Galore 2Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 2Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 3
... , FRIDAY, Jan. 14 (HealthDay News) -- Researchers have ... risk of cardiovascular disease, while also noting that having ... once arteries become clogged. "Certain genes predispose to ... heart attack when you already have plaque build-up," said ...
... ongoing controversy about the appropriate age, frequency, and ... the upcoming 19th Annual Congress on Women,s Health, ... "Point-Counterpoint: The Mammography Controversy" will explore the relevant ... of Radiology, Magee-Womens Hospital, University of Pittsburgh School ...
... HealthDay Reporter , FRIDAY, Jan. 14 (HealthDay News) -- If ... you stand and sit may affect how you feel about ... an interview during these tough economic times, according to a ... Management at Northwestern University in Illinois found that undergraduates who ...
... -- Bacteria that prey on other bacteria may prove useful ... two types of predatory bacteria -- Micavibrio aeruginosavorus ... bacteria. "They actually have to consume other bacteria in ... ability to seek out other bacteria, invade them, grow in ...
... News) -- Obese black patients receive less weight reduction and ... study finds. The researchers at the Johns Hopkins University ... to find that white patients treated by black doctors were ... black patients treated by black doctors. "Our findings could ...
... , FRIDAY, Jan. 14 (HealthDay News) -- ... to become primary care doctors, who are expected to ... contends a new study from Johns Hopkins. They,re ... problems as diabetes, hypertension and high cholesterol, the study ...
Cached Medicine News:Health News:Blood Type O Associated With Less Risk for Heart Attack 2Health News:Blood Type O Associated With Less Risk for Heart Attack 3Health News:Mammography controversy to be explored at 19th Annual Congress on Women's Health 2Health News:To Nab That Job, Check Your Posture 2Health News:To Nab That Job, Check Your Posture 3Health News:Predatory Bacteria May Help Control Antibiotic-Resistant Germs 2Health News:Is Race a Factor in Obesity Counseling? 2Health News:Med School Grads May Not Be Ready for Primary Care 2
For the quantitative determination of total protein in serum. Linearity: 1-15 g/dl....
For the determination of urea nitrogen in human serum....
... for the quantitative determination of ... kinetic, lag phase of less ... linear phase of at least ... Linearity: 100 mg/dL (35.6 mmol/L ...
Intended for the quantitative determination of urea nitrogen in serum. Reaction: kinetic. Wavelength: 340 nm. Linearity: 150 mg/dL (53.4 mmol/L urea) at 37C....
Medicine Products: